Trial Profile
Response to aflibercept in patients with persistent exudation despite prior treatment with bevacizumab or ranibizumab for age-related macular degeneration.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Nov 2015
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 12 Nov 2015 New trial record